Biopharma prediction markets raise insider-info concerns, regulators weigh oversight

Prediction markets are emerging as platforms where participants can wager on biopharma events such as clinical trial results and FDA approvals. The format allows crowds to aggregate expectations about drug development outcomes.

The growth of these markets raises concerns about the possible use of non-public information. Employees, researchers or contractors with confidential data could gain an unfair advantage, prompting regulators to consider how to enforce insider-trading rules in this new context.

Experts suggest companies should tighten information barriers, train staff on compliance and monitor market activity to reduce the risk of leaks. Ongoing dialogue with regulators will be key as the industry adapts to these betting platforms.